Almirall (ALM.MC) Stock Price

Almirall Price

BME·CLOSED
11.12EUR+0.02 (+0.18 %)
Market closed

Over the last 19 years Almirall grew revenue by 1.8% annually, reaching 1.11 B EUR. Earnings per share have declined at 8.6% per year over the last 16 years. For Almirall, the net margin of 4.2% is up versus -4.9% a few years ago. At today's price the dividend yield works out to roughly 1.65%. The payout ratio is around 85% of earnings. The consensus 12-month price target for Almirall is 14.28 EUR, about 28.4% above where the stock trades today. Of 17 analysts, 12 rate the stock a buy — an overall Buy consensus. The stock trades about 9% above its 52-week low.

Almirall stock price

Volume
Ex-Dividend
Details

Stock Price

ⓘ

How to Read This Chart

This chart tracks the historical stock price of Almirall over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Almirall stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Almirall's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

Almirall Stock Price History
DateAlmirall Price
8/3/202611.12 EUR
7/31/202611.10 EUR
7/30/202611.32 EUR
7/29/202611.46 EUR
7/28/202611.42 EUR
7/27/202611.26 EUR
7/24/202611.20 EUR
7/23/202611.04 EUR
7/22/202610.94 EUR
7/21/202610.90 EUR
7/20/202610.94 EUR
7/17/202610.72 EUR
7/16/202610.64 EUR
7/15/202610.66 EUR
7/14/202610.74 EUR
7/13/202610.94 EUR
7/10/202611.24 EUR
7/9/202611.48 EUR
7/8/202611.48 EUR
7/7/202611.70 EUR
7/6/202611.50 EUR
7/3/202611.36 EUR
7/2/202611.58 EUR
7/1/202611.22 EUR
6/30/202611.26 EUR
6/29/202611.34 EUR
6/26/202611.28 EUR
6/25/202611.32 EUR
6/24/202611.26 EUR
6/23/202611.26 EUR
6/22/202611.18 EUR
6/19/202611.24 EUR
6/18/202611.26 EUR
6/17/202611.30 EUR
6/16/202611.34 EUR
6/15/202611.48 EUR
6/12/202611.48 EUR
6/11/202611.22 EUR
6/10/202611.08 EUR
6/9/202611.08 EUR
6/8/202611.20 EUR
6/5/202611.32 EUR
6/4/202611.00 EUR
6/3/202610.96 EUR
6/2/202611.04 EUR
6/1/202611.36 EUR
5/29/202611.62 EUR
5/28/202611.56 EUR
5/27/202611.78 EUR
5/26/202611.76 EUR
5/25/202611.76 EUR
5/22/202611.50 EUR
5/21/202611.34 EUR
5/20/202611.18 EUR
5/19/202611.18 EUR
5/18/202611.30 EUR
5/15/202611.32 EUR
5/14/202611.50 EUR
5/13/202611.62 EUR
5/12/202611.64 EUR
5/11/202611.64 EUR
5/8/202611.96 EUR
5/7/202612.10 EUR
5/6/202612.22 EUR
5/5/202612.34 EUR
5/4/202612.32 EUR
4/30/202612.58 EUR
4/29/202612.42 EUR
4/28/202612.58 EUR
4/27/202612.58 EUR
4/24/202612.72 EUR
4/23/202612.84 EUR
4/22/202612.82 EUR
4/21/202612.72 EUR
4/20/202612.78 EUR
4/17/202612.78 EUR
4/16/202612.68 EUR
4/15/202613.08 EUR
4/14/202613.40 EUR
4/13/202613.06 EUR
4/10/202613.00 EUR
4/9/202612.72 EUR
4/8/202612.42 EUR
4/7/202612.30 EUR
4/2/202612.30 EUR
3/27/202612.00 EUR
3/26/202611.93 EUR
3/25/202611.56 EUR
3/24/202611.40 EUR
3/23/202611.39 EUR
3/20/202611.42 EUR
3/19/202611.18 EUR
3/17/202611.44 EUR
3/16/202611.48 EUR
3/13/202611.45 EUR
3/12/202611.64 EUR
3/11/202611.77 EUR
3/10/202612.08 EUR
3/9/202611.84 EUR
3/6/202612.06 EUR
3/5/202612.16 EUR
2/27/202612.95 EUR
2/26/202612.86 EUR
2/25/202613.10 EUR
2/23/202613.01 EUR
2/20/202613.53 EUR
2/19/202613.87 EUR
2/18/202613.80 EUR
2/17/202613.51 EUR
2/16/202613.47 EUR
2/13/202613.33 EUR
2/12/202613.40 EUR
2/11/202613.62 EUR
2/10/202613.22 EUR
2/9/202612.96 EUR
2/6/202612.93 EUR
2/5/202612.98 EUR
2/4/202612.94 EUR
2/3/202612.77 EUR
2/2/202612.54 EUR
1/30/202612.61 EUR
1/29/202612.32 EUR
1/28/202612.40 EUR
1/27/202612.70 EUR
1/26/202612.69 EUR
1/23/202612.86 EUR
1/22/202612.48 EUR
1/21/202612.36 EUR
1/20/202612.38 EUR
1/19/202612.81 EUR
1/16/202613.28 EUR
1/15/202613.18 EUR
1/14/202613.21 EUR
1/13/202613.12 EUR
1/12/202613.18 EUR
1/9/202613.17 EUR
1/8/202613.53 EUR
1/7/202613.35 EUR
1/6/202613.18 EUR
1/5/202613.15 EUR
1/2/202612.88 EUR
12/31/202512.84 EUR
12/30/202512.90 EUR
12/29/202512.90 EUR
12/24/202512.90 EUR
12/23/202513.04 EUR
12/22/202512.94 EUR
12/19/202512.97 EUR
12/18/202512.90 EUR
12/17/202512.84 EUR
12/16/202512.87 EUR
12/15/202513.31 EUR
12/12/202513.27 EUR
12/11/202513.10 EUR
12/10/202512.98 EUR
12/9/202513.04 EUR
12/8/202513.15 EUR
12/5/202513.00 EUR
12/4/202512.83 EUR
12/3/202512.77 EUR
12/2/202512.80 EUR
12/1/202512.63 EUR
11/28/202512.57 EUR
11/27/202512.51 EUR
11/26/202512.65 EUR
11/25/202512.70 EUR
11/24/202512.57 EUR
11/21/202512.43 EUR
11/20/202512.53 EUR
11/19/202512.34 EUR
11/18/202512.23 EUR
11/17/202512.36 EUR
11/14/202512.28 EUR
11/13/202512.34 EUR
11/12/202512.33 EUR
11/11/202511.96 EUR
11/10/202512.24 EUR
11/7/202511.58 EUR
11/6/202511.81 EUR
11/5/202512.02 EUR
11/4/202512.09 EUR
11/3/202512.29 EUR
10/31/202512.48 EUR
10/30/202512.48 EUR
10/29/202512.68 EUR
10/28/202512.65 EUR
10/27/202512.46 EUR
10/24/202512.34 EUR
10/23/202512.23 EUR
10/22/202512.07 EUR
10/21/202511.90 EUR
10/20/202512.02 EUR
10/17/202512.07 EUR
10/16/202511.98 EUR
10/15/202511.97 EUR
10/14/202512.14 EUR
10/13/202512.00 EUR
10/10/202511.99 EUR
10/9/202511.94 EUR
10/8/202511.87 EUR
10/7/202511.88 EUR
10/6/202512.02 EUR
10/3/202511.93 EUR
10/2/202511.83 EUR
10/1/202511.87 EUR
9/29/202511.32 EUR
9/26/202511.22 EUR
9/25/202511.30 EUR
9/24/202511.51 EUR
9/23/202511.41 EUR
9/22/202511.54 EUR
9/19/202511.52 EUR
9/18/202511.23 EUR
9/17/202511.14 EUR
9/16/202511.19 EUR
9/15/202511.21 EUR
9/12/202511.12 EUR
9/11/202511.26 EUR
9/10/202511.16 EUR
9/9/202511.09 EUR
9/8/202511.20 EUR
9/5/202511.03 EUR
9/4/202511.17 EUR
9/3/202511.20 EUR
9/2/202511.25 EUR
9/1/202511.23 EUR
8/29/202511.21 EUR
8/28/202511.29 EUR
8/27/202511.16 EUR
8/26/202511.08 EUR
8/25/202511.14 EUR
8/22/202511.20 EUR
8/21/202511.06 EUR
8/20/202511.02 EUR
8/19/202511.21 EUR
8/18/202511.20 EUR
8/15/202511.24 EUR
8/14/202511.14 EUR
8/13/202510.86 EUR
8/12/202510.38 EUR
8/11/202510.42 EUR
8/8/202510.28 EUR
8/7/202510.24 EUR
8/6/202510.24 EUR
8/5/202510.32 EUR
8/4/202510.30 EUR
Access this data via the Eulerpool API
Get Free API Key

Almirall Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2023
894.52 M EUR
-5.26 M EUR
-38.47 M EUR
Jan 1, 2024
985.72 M EUR
36.09 M EUR
10.15 M EUR
Jan 1, 2025
1.11 B EUR
67.71 M EUR
46.20 M EUR
Jan 1, 2026 (e)
1.23 B EUR
34.96 M EUR
84.07 M EUR
Jan 1, 2027 (e)
1.35 B EUR
38.55 M EUR
114.26 M EUR
Jan 1, 2028 (e)
1.48 B EUR
42.03 M EUR
150.26 M EUR
Jan 1, 2029 (e)
1.60 B EUR
45.61 M EUR
185.40 M EUR
Jan 1, 2030 (e)
1.68 B EUR
47.90 M EUR
203.51 M EUR

Almirall Income Statement, Balance Sheet, Cash Flow Statement

Last updated Aug 3, 2026, 12:17 PM
 
REVENUEB EUR
REVENUE GROWTH%
GROSS MARGIN%
GROSS INCOMEB EUR
EBITM EUR
EBIT MARGIN%
NET INCOMEM EUR
NET INCOME GROWTH%
DIV.EUR
DIV. GROWTH%
SHARESM
201520162017201820192020202120222023202420252026e2027e2028e2029e2030e
0.690.760.640.760.861.610.830.860.890.991.111.231.351.481.601.68
-15.8710.89-16.3618.3113.1088.77-48.764.353.5910.1812.4910.8310.269.088.465.06
78.0878.6672.9378.5777.4389.2879.2078.7964.5477.8741.1641.1641.1641.1641.1641.16
0.540.600.470.590.661.440.660.680.580.770.460.510.560.610.660.69
168.00130.00-299.0086.00149.0092.00105.0046.00-5.0036.0067.0034.0038.0042.0045.0047.00
24.3817.02-46.7911.3817.435.7012.705.33-0.563.656.052.772.812.842.812.79
131.0075.00-303.0077.00105.0074.00-40.004.00-38.0010.0046.0084.00114.00150.00185.00203.00
-70.76-42.75-504.00-125.4136.36-29.52-154.05-110.00-1,050.00-126.32360.0082.6135.7131.5823.339.73
0.200.190.190.180.200.200.190.190.180.180.180.180.180.18––
–-5.00–-5.2611.11–-10.005.56-5.26–––––––
166.92172.95172.95175.88173.57178.91179.78181.52209.39213.47214.67214.67214.67214.67214.67214.67
Details

Income Statement Key Figures

ⓘ

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales Almirall generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Almirall retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Almirall's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares Almirall has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Almirall's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

Almirall stock margins

The Almirall margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Almirall. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Almirall.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2021
79.26 %
12.74 %
-4.94 %
Jan 1, 2022
78.86 %
5.43 %
0.50 %
Jan 1, 2023
64.52 %
-0.59 %
-4.30 %
Jan 1, 2024
77.88 %
3.66 %
1.03 %
Jan 1, 2025
41.21 %
6.11 %
4.17 %
Jan 1, 2026 (e)
41.21 %
2.85 %
6.84 %
Jan 1, 2027 (e)
41.21 %
2.85 %
8.44 %
Jan 1, 2028 (e)
41.21 %
2.85 %
10.17 %

Almirall Stock Revenue, EBIT, Earnings per Share

The Almirall earnings per share therefore indicates how much revenue Almirall has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2021
4.60 EUR
0.59 EUR
-0.23 EUR
Jan 1, 2022
4.76 EUR
0.26 EUR
0.02 EUR
Jan 1, 2023
4.27 EUR
-0.03 EUR
-0.18 EUR
Jan 1, 2024
4.62 EUR
0.17 EUR
0.05 EUR
Jan 1, 2025
5.16 EUR
0.32 EUR
0.22 EUR
Jan 1, 2026 (e)
5.70 EUR
0.16 EUR
0.39 EUR
Jan 1, 2027 (e)
6.29 EUR
0.18 EUR
0.53 EUR
Jan 1, 2028 (e)
6.86 EUR
0.20 EUR
0.70 EUR

Almirall business model & stock analysis

The company Almirall SA is a globally operating pharmaceutical company headquartered in Barcelona, Spain. Founded in 1943 by Antonio Gallardo Ballart, the company has since become one of the leading companies in the field of dermatology and respiratory diseases. Almirall specializes in the development, manufacturing, and marketing of medications used in the treatment of skin conditions such as psoriasis or eczema, as well as respiratory diseases such as asthma or chronic bronchitis. The company focuses on close collaboration with doctors and patients to achieve the best possible therapeutic success. Almirall's business model is based on collaboration with other pharmaceutical companies to develop and bring innovative medications to the market. The company has its own research and development departments and also conducts clinical trials to test the safety and efficacy of new medications. Additionally, Almirall operates its own network of distribution and marketing partners to distribute its products worldwide. Almirall is organized into three divisions: dermatology, respiratory diseases, and other therapeutic areas. The dermatology division includes the development and marketing of medications for the treatment of skin conditions such as psoriasis and eczema. Some examples of products in this division are Skilarence, a medication for the treatment of moderate to severe psoriasis, and Kigozi, a topical medication for the treatment of atopic dermatitis. The respiratory diseases division includes the development and marketing of medications for the treatment of asthma and chronic bronchitis. The company offers a wide range of medications in this area that can be used in inhalation or tablet therapy. Some of the well-known products in this division are Alvesco, an inhaled corticosteroid for the treatment of asthma, and Ebastel, a medication for the treatment of allergic reactions. In other therapeutic areas, Almirall is involved in the development of new medications for the treatment of diseases such as ulcerative colitis or schizophrenia. For example, the company has developed Sativex, a cannabis-based medication for the treatment of multiple sclerosis-related spasticity, which is already approved in several countries. Throughout its history, Almirall has received numerous awards and recognition, including for the development of innovative medications and its work in the field of sustainability and corporate social responsibility. Through its commitment to research and development and collaboration with other pharmaceutical companies, Almirall will continue to play an important role in the global pharmaceutical industry market.

Almirall SWOT Analysis

Strengths

Almirall SA possesses several key strengths that contribute to its competitive advantage in the market. These include:

  • Strong brand reputation and recognition globally
  • Diverse portfolio of innovative pharmaceutical products
  • Strong research and development capabilities
  • Robust distribution network and strong partnerships

Weaknesses

Despite its strengths, Almirall SA also faces certain weaknesses that may hinder its growth and performance. These include:

  • Overdependence on a limited number of key products
  • Relatively small market share compared to industry leaders
  • Vulnerability to changes in government regulations
  • Higher production costs compared to some competitors

Opportunities

Almirall SA has various opportunities in the market that it can capitalize on for future growth. These opportunities include:

  • Increasing global demand for dermatological and respiratory treatments
  • Expansion into emerging markets with rising healthcare spending
  • Growing trend of research and development collaborations in the industry
  • Introduction of new drugs and therapies targeting unmet medical needs

Threats

Almirall SA also faces several threats that may pose challenges to its business operations and profitability. These threats include:

  • Intense competition from well-established pharmaceutical companies
  • Increase in generic drug manufacturing and pricing pressure
  • Rapid advancements in technology impacting the industry
  • Stringent regulations and requirements for product approvals

Almirall Eulerpool Fair Value

Details

Fair Value Estimate

ⓘ

What Is Fair Value?

Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.

Earnings-Based Fair Value

Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.

Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021

Revenue-Based Fair Value

Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"

Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021

Dividend-Based Fair Value

Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.

Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021

How to Use This Chart

When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.

Almirall historical P/E ratio, EBIT multiple, and P/S ratio

Almirall annual returns

Details

Annual Return

ⓘ

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

Almirall shares outstanding

The number of shares of Almirall was 214.67 M in 2025. This indicates how many shares Almirall is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2021
179.78 M Stocks
Jan 1, 2022
181.52 M Stocks
Jan 1, 2023
209.39 M Stocks
Jan 1, 2024
213.47 M Stocks
Jan 1, 2025
214.67 M Stocks
Jan 1, 2026 (e)
214.67 M Stocks
Jan 1, 2027 (e)
214.67 M Stocks
Jan 1, 2028 (e)
214.67 M Stocks

Almirall Dividend History

17 years of dividend payments

YearAnnual DividendYoY ChangePayments
20250.18EUR 0.0%1×
May 15, 20250.18EUR 0.0%1/1
20240.18EUR 0.0%1×
20230.18EUR↓ 1.1%1×
20220.19EUR↑ 0.5%1×
20210.19EUR↓ 6.6%1×
20200.20EUR↓ 2.5%1×
20190.20EUR↑ 10.3%1×
20180.18EUR↓ 3.2%1×
20170.19EUR 0.0%1×
20160.19EUR↓ 5.0%1×

Almirall dividend history and estimates

In 2025, Almirall paid a dividend amounting to 0.18 EUR. Dividend means that Almirall distributes a portion of its profits to its owners.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Dividend
Dividend (Estimate)
Details
Date
Dividend
Dividend (Estimate)
Jan 1, 2021
0.19 EUR
0.00 EUR
Jan 1, 2022
0.19 EUR
0.00 EUR
Jan 1, 2023
0.18 EUR
0.00 EUR
Jan 1, 2024
0.18 EUR
0.00 EUR
Jan 1, 2025
0.18 EUR
0.00 EUR
Jan 1, 2026 (e)
0.00 EUR
0.18 EUR
Jan 1, 2027 (e)
0.00 EUR
0.18 EUR
Jan 1, 2028 (e)
0.00 EUR
0.18 EUR

Almirall dividend payout ratio

In 2025, Almirall had a payout ratio of 85.50%. The payout ratio indicates the percentage of the company's profits that Almirall distributes as dividends.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Payout ratio
Details
Date
Payout ratio
Jan 1, 2021
-80.62 %
Jan 1, 2022
772.55 %
Jan 1, 2023
-100.14 %
Jan 1, 2024
336.19 %
Jan 1, 2025
85.50 %
Jan 1, 2026 (e)
47.13 %
Jan 1, 2027 (e)
34.68 %
Jan 1, 2028 (e)
26.37 %

Current Almirall forecasts and price targets in August 2026

Analyst Price Targets 2026
Δ MOM Price Target
3.70 %
Buy
70.59 % (12)
Hold
29.41 % (5)
Sell
0.00 % (0)
12M Price Target
14.28
Last Price
11.10
Currency
EUR
12M Return Potential
28.65 %
LTM Return
0 %

Almirall Analyst Rating Actions

DateFirmActionRatingReliability
9/8/2021
Morgan Stanley
Morgan Stanley
MaintainedOverweight60

Eulerpool Reliability Score (0–100): measures how often a firm’s bullish or bearish calls were directionally correct three months later, blended with the average return following its calls. Every rating we record is stored permanently and scores update continuously; firms with fewer than 3 measured calls are not scored yet.

Almirall Earnings Calls

2025

Almirall Earnings Estimates & Surprises

DateEPS estimateEPS ActualRevenue EstimatePrice reactionQuarterly report
11/10/20220.05EUR-208.21 MEUR-2022 Q3
7/25/20220.05EUR-217.18 MEUR-2022 Q2
5/9/20220.06EUR-222.68 MEUR-2022 Q1
2/21/20220.02EUR-202.42 MEUR-2021 Q4
11/15/20210.07EUR-195.89 MEUR-2021 Q3
7/26/20210.10EUR-204.83 MEUR-2021 Q2
5/10/20210.11EUR-203.98 MEUR-2021 Q1
2/22/20210.10EUR-204.43 MEUR-2020 Q4
11/9/20200.06EUR-190.24 MEUR-2020 Q3
7/27/20200.07EUR-196.47 MEUR-2020 Q2

EESG©

Eulerpool ESG Scorecard© for the Almirall stock

78/100
99
Environment
99
Social
37
Governance
E

Environment

20
Scope 1 - Direct Emissions6,154
Scope 2 - Indirect emissions from purchased energy4,868
Scope 3 - Indirect emissions within the value chain156,670
Total CO₂ emissions11,022
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather—
Pesticides—
Palm Oil—
Tobacco
Genetically modified organisms
Climate concept—
Sustainable forestry—
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency
S

Social

20
Percentage of female employees54
Percentage of women in management—
Percentage of Asian employees—
Share of Asian management—
Percentage of Hispanic/Latino employees—
Hispano/Latino Management share—
Percentage of Black employees—
Black Management Share—
Percentage of white employees—
White Management Share—
Adult content
Alcohol
Weapons—
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept—
Occupational health and safety
Catholic
G

Governance (Corporate Governance)

4
Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Almirall shareholder structure

% Name
59.72288%
Gallardo Ballart family
Gallardo Ballart family
5.02366%
Norbel Invesrsiones, S.L.
Norbel Invesrsiones, S.L.
2.39536%
Oddo BHF Asset Management S.A.S
Oddo BHF Asset Management S.A.S
1.22940%
Cobas Asset Management, SGIIC, SA
Cobas Asset Management, SGIIC, SA
1.10632%
The Vanguard Group, Inc.
The Vanguard Group, Inc.
1.04804%
Caixabank Asset Management SGIIC, S.A.U.
Caixabank Asset Management SGIIC, S.A.U.

Almirall Beneficial Ownership Filings (SEC 13D/G)

Free Float
34.7%
Float Shares
-
Shares Outstanding
-

Almirall Executives and Management Board

22 members · avg. age 60 · 27 % women

CP

Mr. Carlos Gallardo Pique (52)

Executive Chairman of the Board, Chief Executive Officer · since 2014

1.71 M EUR

Management

PR

Mr. Paul Rittman

President, General Manager - Almirall, US

–
MM

Mr. Michael James Mcclellan

Chief Financial Officer

–
ML

Ms. Mercedes Diz Lopez

Chief Marketing Officer

–
KZ

Mr. Karl Ziegelbauer

Chief Scientific Officer

–
IG

Ms. Isabel Cristina Gomez

Chief Legal Officer, General Counsel, Non-Member Vice-Secretary of the Board

–
PC

Mr. Paolo Cionini

Chief Commercial Officer, Europe & International · since 2023

–

Board of Directors

EP

Mr. Enrique De Leyva Perez (65)

Independent Vice Chairman of the Board

174,000.00 EUR
SO

Dr. Seth Orlow (66)

Independent Director

153,000.00 EUR
AK

Dr. Alexandra B. Kimball (56)

Independent Director

148,000.00 EUR
EC

Mrs. Eva-Lotta Allan Coulter (65)

Independent Director

145,000.00 EUR
RD

Dr. Ruud Dobber (60)

Independent Director

140,000.00 EUR
KD

Dr. Karin Dorrepaal (63)

Independent Director

140,000.00 EUR

Frequently asked questions about Almirall

The business model of Almirall SA focuses on the pharmaceutical industry. Almirall SA is a global biopharmaceutical company that specializes in the research, development, and commercialization of innovative medicines. They operate primarily in the fields of dermatology, gastroenterology, and respiratory diseases, offering a diversified portfolio of pharmaceutical products. Almirall SA aims to meet patient needs by delivering high-quality and effective medicines while maintaining a strong commitment to research and development. Through strategic partnerships and collaborations, Almirall SA strives to improve the health and well-being of people worldwide with their innovative solutions.

Almirall SA is primarily active in the pharmaceutical industry.

The main competitors of Almirall SA in the market include prominent pharmaceutical companies such as AstraZeneca, Novartis, Johnson & Johnson, and GlaxoSmithKline.

Almirall SA, a leading pharmaceutical company, has a rich history and a strong background. Founded in 1943 in Barcelona, Spain, Almirall has been dedicated to improving people's health and well-being for over 75 years. The company specializes in researching, developing, manufacturing, and marketing innovative medicines and healthcare solutions worldwide. With a commitment to scientific excellence and a customer-centric approach, Almirall has established itself as a trusted name in the pharmaceutical industry. Continuously expanding its product portfolio and collaborating with valued partners, Almirall strives to meet the evolving needs of patients and healthcare professionals, driving advancements and reshaping the future of healthcare.

Almirall SA has achieved several significant milestones in its corporate history. Over the years, the company has successfully developed and marketed innovative pharmaceutical products. Notably, Almirall SA has gained regulatory approvals for a range of therapeutic solutions, such as dermatology treatments and respiratory medicines. The company has also expanded its global presence and entered into strategic partnerships to enhance its research and commercial capabilities. Almirall SA continues to strive for excellence in the healthcare industry, focusing on the development of novel therapies to improve patients' lives and maintain its position as a leading pharmaceutical company.

Almirall SA is primarily present in various countries and regions worldwide. The company has a significant presence in Europe, including Spain, where it is headquartered. Additionally, Almirall SA operates in several countries across the Americas, including Mexico, Brazil, and Colombia. The company also has a growing presence in Asia, particularly in China and Japan. Almirall SA's global reach enables it to serve a diverse customer base and leverage different market opportunities.

Almirall SA represents values of innovation, integrity, and excellence in the pharmaceutical industry. The company is committed to improving patients' lives by developing and providing effective and safe medical solutions. Almirall SA strives for scientific advancement and collaboration to address unmet medical needs. With a strong corporate philosophy focused on patient-centricity and sustainability, Almirall SA aims to deliver high-quality healthcare products and services worldwide. Through its dedication to research and development, this global pharmaceutical company seeks to make a positive impact on patients, healthcare professionals, and society as a whole.

Analysts currently set an average price target of 14.22 EUR for the Almirall stock (median: 14.28 EUR), implying +28.1 % versus the latest price. The consensus is based on 17 analyst ratings.

Almirall Analyst Price Targets 2026

17 analysts currently rate the Almirall stock: 12 recommend buying, 5 holding and 0 selling. For 2026, analysts expect Almirall to generate revenue of 1.23 B EUR and earnings per share of 0.39 EUR.

Almirall Analyst Price Targets 2026

The Almirall share (ALM.MC) is listed on 8 stock exchanges, including: Frankfurt (E2Z.F), München (E2Z.MU), Düsseldorf (E2Z.DU), London (0O9B.L).

Almirall SA is a pharmaceutical company based in Spain. The company focuses on researching and developing medications for the treatment of respiratory and dermatology conditions, as well as pain and inflammatory diseases.

The expected revenue of Almirall is 1.23 B EUR. This figure is based on current financial data and reflects the company's business performance.

The expected profit of Almirall is 84.07 M EUR. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Almirall is currently 28.39. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Almirall stock.

The price-to-sales ratio (P/S) of Almirall is currently 1.94. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Almirall stock.

The Eulerpool Quality Score for Almirall is 4/10.

The ISIN of Almirall is ES0157097017. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of Almirall is A0MU8Y. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of Almirall is ALM.MC. The ticker symbol is used to trade Almirall shares on the stock exchange.

Over the past 12 months, Almirall paid a dividend of 0.18 EUR . This corresponds to a dividend yield of about 1.65 %. For the coming 12 months, Almirall is expected to pay a dividend of 0.18 EUR.

The current dividend yield of Almirall is 1.65 %.

Almirall pays a dividend, distributed in the months of , , , .

Almirall paid dividends every year for the past 11 years.

For the upcoming 12 months, dividends amounting to 0.18 EUR are expected. This corresponds to a dividend yield of 1.66 %.

Almirall is assigned to the 'Health' sector.

To receive the latest dividend of Almirall from amounting to 0.18 EUR, you needed to have the stock in your portfolio before the ex-date on .

The last dividend was paid out on .

In the year 2025, Almirall distributed 0.18 EUR as dividends.

The dividends of Almirall are distributed in EUR.

All fundamentals and in-depth analysis of Almirall

Our stock analysis for Almirall stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Almirall. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.

Almirall Stock
Almirall Revenue→
Almirall Stock
Almirall Net Income→
Almirall Stock
Almirall P/E→
Almirall Stock
Almirall P/S→
Almirall Stock
Almirall EBIT→
Almirall Stock
Almirall Dividend→
Almirall Stock
Almirall Directors Dealings→
Almirall Stock
Almirall Stocks→
Almirall Stock
Almirall Market capitalization→
Almirall Stock
Almirall Debt→
Almirall Stock
Almirall Liabilities→
Almirall Stock
Almirall Equity→
Almirall Stock
Almirall AAQS→
Almirall Stock
Almirall Employees→
Almirall Stock
Almirall ROE→
Almirall Stock
Almirall ROA→
Almirall Stock
Almirall ROCE→
Almirall Stock
Almirall News→
Almirall Stock
Almirall Analyst Price Targets→

Health Stocks

Almoosa Health Company SJSCAllogene TherapeuticsAlnylam PharmaceuticalsAllmed SolutionsAlpa LaboratoriesAllmed Medical Products CoAlpha CognitionAlligator BioscienceAlpha Tau MedicalAllied BiotechAlpha TeknovaAlliedAll Stocks A–Z →